A carrier‐free peptide–cyclic dinucleotide (CDN) nanoconjugate (PCN) is developed that co‐activates immunogenic cell death (ICD) in tumors and stimulator of interferon genes (STING) signaling in DCs and broadly reprogrammed the tumor microenvironment toward anti‐tumor immunity.
Abstract
In vivo immune modulation can potentially benefit broader cancer patients. Efficient cross‐priming of anti‐tumor T cells requires “three‐signal” dendritic cells (DCs) that simultaneously integrate antigenic, co‐stimulatory, and migratory programs, which remains a major challenge. Here, we developed a carrier‐free peptide–cyclic dinucleotide (CDN) nanoconjugate (PCN) that co‐activates immunogenic cell death (ICD) in tumors and stimulator of interferon genes (STING) signaling in DCs. Library screening identified ICD‐inducing peptides enriched in hydrophobic and cationic residues that promote self‐assembly, cell penetration, and ICD potency. Mechanistic studies revealed peptides can trigger overlapping pyroptosis, necroptosis, and apoptosis, with lysosomal damage and cathepsin release as dominant upstream drivers. PCN promoted tumor‐antigen release and facilitated cytosolic CDN delivery for robust STING activation. This dual functionality induced early cytokine and chemokine responses and generated cDC1‐enriched “three‐signal” migratory DCs trafficking from tumors to draining lymph nodes, resulting in enhanced antigen‐specific CD8+ T‐cell activation and memory formation. PCN also broadly reprogrammed the tumor microenvironment toward anti‐tumor immunity. In preclinical models, PCN induced complete tumor rejection in 70% of B16‐F10‐ or CT26‐bearing mice and provided durable protection against tumor rechallenge when combined with α‐PD‐1.
Insufficient tumor‐targeting accumulation and the immunosuppressive tumor microenvironment (TME) greatly restrict the efficacy of chemo‐immunotherapy. Herein, AWS@PTNC nanoparticles (NPs) are elaborately fabricated via self‐assembly of paclitaxel dimer and serine synthesis inhibitor, followed by surface modification...
ABSTRACT Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen‐presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist...
Yang-Fan Wu, Jing-Chu Hu, Ye-Fan Hu et al.· Advancement of science· 0 citations
Oncolytic adenovirus (OA) exhibit tumor‐selective tropism, inducing direct oncolysis while simultaneously potentiating host immune responses against malignancies. However, the poor delivery efficiency of the virus targeting tumors and its limited immune activation capacity severely delays the therapeutic effect. This s...
Yu-Qing Lv, Qing-Yuan Wu, Ao-Di Niu et al.· Advances in Materials· 0 citations
ABSTRACT Breast cancer is the most commonly diagnosed cancer worldwide and a leading cause of cancer‐related mortality in women. Despite therapeutic advances, treating advanced or recurrent cases is substantially hampered by drug resistance and the immunosuppressive tumor microenvironment (TME). Here, we report a break...
Su-Jin Kang, Gichan Baek, Su-Wun Ju et al.· Journal of Extracellular Ves...· 0 citations
ABSTRACT Tumor‐resident intracellular bacteria (TRIB) are prevalent within triple‐negative breast cancer (TNBC). As integral components of the tumor pathological microenvironment, TRIB accelerate TNBC development by regulating cell proliferation, metabolism and immunosuppression. They also enhance the resistance of cir...
X. Leng, Tao Jiang, Zhao Guo et al.· Advancement of science· 0 citations
Identifying targets to enhance tumor immunity is an urgent need. Although nucleic acid sensors play critical roles in promoting tumor immune clearance, their exceptionally low mutation rate in cancers suggests potential unexplored roles in tumor progression. Here, we demonstrate that the RNA sensor melanoma differentia...